DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Asahi Intecc Partners with Penumbra; Prosoma and EVERSANA Announce Commercialisation Partnership; Zynex Starts Enrollment in the Blood Loss Detection Clinical Trial; Reva Initiates Enrollment in the MOTIV IDE Clinical Trial; FDA Clearance to QT Imaging to Calculate Fibroglandular Volume of the Breast; FDA 510k Clearance to iMediSync’s EEG scanner ‘iSyncWave’ Visit Post
2 Daiichi Sankyo’s Ezharmia; Pfizer & Sangamo Hemophilia A Gene Therapy Trial; Approval for Fennec's Pedmark; FDA Approves UBE and Santen’s OMLONTI; EC Approves AstraZeneca’s Tezspire; FDA Approves Selpercatinib; FDA Grants Accelerated Approval to Eli Lilly’s Retevmo; GSK & Spero Announce Exclusive License Agreement Visit Post
3 AstraZeneca’s Danicopan Trial; CHMP Recommends Sanofi/AstraZeneca’s nirsevimab; Akero’s NASH Drug Trial; FDA Grants Orphan Drug Status to SY-5609; BMS’s Opdivo Trial Results; Pfizer to File for FDA Approval for Meningitis Vaccine; EMA Orphan Drug Designation to CAN-2409; FDA Starts Priority Review of Chiesi ‘s velmanase alfa Visit Post
4 Amgen Announced the Result of its CodeBreak-200 Trial; FDA Clears Bristol-Myers Squibb’s Deucravacitinib; BioNTech’s Amplified CAR-T Therapy; TIL Therapy Improves on Yervoy in Melanoma; GSK’s Daprodustat will have to face FDA Advisory Committee; Breakthrough Therapy Status to Pfizer’s Group B Strep Vaccine; EU Approves Gilead’ Tecartus; Gilead’ Trodelvy Results in TROPiCs-02 Trial Visit Post
5 Treatment to Clinical Development – A Bumpy Journey for Pancreatic Cancer Visit Post
6 AstraZeneca’s Imfinzi for Biliary Tract Cancer; FDA Clears Boehringer’s Spesolimab; Novo Nordisk to Acquire Forma Therapeutics; Sanofi’s Xenpozyme Approved for ASMD; Another FDA Approval to Azurity’s Konvomep; Amgen’s Lumakras Trial Results; FDA Grants Priority Review to Sanofi & Sobi’s efanesoctocog alfa; Neurocrine Bio to Takeover UK Biotech Diurnal Visit Post
7 Edwards’s Pascal Precision System; Abbott's New Spinal Cord Stimulation Device; Imagin to Acquire enCAGE Coil Precision Ablation System; Boston Heart Diagnostics Launches LipidSeqTM; Rocket VR Health Partners with Penn Medicine’s Abramson Cancer Center; Thermedical’s Clinical Trial to Treat Ventricular Tachycardia Visit Post
8 EMA to review Cidara Therapeutics’ Rezafungin; EU Approves Gilead Sciences’ Sunlenca; FDA Approves Axsome’s Auvelity; EU Marketing Authorisation to Oncopeptides’s Pepaxti; Merck Signs $ 3.5 B Deal with Orna; FDA to review AstraZeneca and Merck’s Lynparza; FDA Approval to Bluebird’s Zynteglo; FDA Decision Date for GSK’s Momelotinib Visit Post
9 AAV Vectors in Gene Therapy: How Recent Clinical Advances are Unraveling New Potentials? Visit Post
10 CereVasc’s eShunt System Study; FDA Approves NGS-Based CDx for Trastuzumab Deruxtecan; Nanopath Secures $10 Million Funding; BD, Accelerate Diagnostics Announce Collaboration; Avails Medical’s Clinical Trials for eQUANT; Movano Ring Exceeds Accuracy Targets for SpO2 & Heart Rate Monitoring Visit Post
11 Novartis’ Canakinumab for NSCLC; Novartis’s Zolgensma Updates; Trodelvy Prospects in New Breast Cancer Use; Novartis Secures European Approval For Pluvicto; Bristol-Myers Squibb’s Abecma Phase III Trials; Trastuzumab Approved for Deruxtecan for HER2-Mutant NSCLC Visit Post
12 FDA Approves AstraZeneca’s Enhertu; Bayer Wins FDA Approval for Prostate Cancer Therapy, Nubeqa; Gilead Sciences to Acquire MiroBio; AstraZeneca & Merck’s Lynparza Gets EU Approval; Pfizer to Acquire Global Blood Therapeutics; Sironax Raises USD 200 Million Visit Post
13 Bristol-Myers Squibb’s Opdivo & Yervoy Combo Trial; Sarepta’s Gene Therapy SRP-9001 for DMD; Ionis’s End-Stage Renal Disease Drugs; FDA Approves Arcutis’s Zoryve Cream; Gilead’s Biktarvy for HIV and Hepatitis B; FDA to Review Biogen’s ALS Therapy Tofersen Visit Post
14 VistaGen’s PH94B for Anxiety Disorder; Keytruda for Head and Neck Cancer Treatment; Bavarian Nordic’s Smallpox Vaccine Imvanex; CAMP4 Raises USD 100 Million; Incyte's WU-CART-007; Incyte’s Opzelura for Vitiligo; AstraZeneca and Merck’s Lynparza; Sumitomo Pharma’s DSP-0390 for Brain Cancer Visit Post
15 FDA Approval to Centinel’s Total Disc Replacement Devices; FDA clears DyAnsys' Neurostimulator; Orthox to Commence FFLEX Study; Cordis Started Enrolment for RADIANCY Clinical Study; Orthofix & LimaCorporate Announce Partnership; Medtronic to Partner With AWS Visit Post
16 Byondis’s HER2-targeting ADC trastuzumab duocarmazine; AbbVie Migraine Drug Atogepant; Grünenthal Acquires Bayer’s Testosterone Drug Rights; Vertex Acquires ViaCyte; Merck & Orion Announces Collaboration; Verve Starts Trials of Cholesterol Drug; Kyowa Kirin Drops Nourianz follow-up KW-6356; FDA Orphan Drug and Fast Track Designations to CV-01 Visit Post
17 Zsquare ENT-Flex Rhinolaryngoscope Receives FDA Clearance; ClearMind Biomedical's Completion of Least Invasive ICH Treatment; Bruker Launched Tool for ‘Long COVID’ Multi-Organ Risk Assessment; EarlySign, Roche Signed Strategic Deal; FDA Clearance for Leva® Pelvic Health System; NeuroOne’s Evo® sEEG Electrode Visit Post
18 Novo Nordisk’s Concizumab for Hemophilia; AbbVie Ends its Alliance with Alector; ADC Therapeutics and Sobi Enters in Exclusive Licensing Deal; BMS’ Opdivo Gets NHS Use; Merck to Acquire Seagen; FDA Priority Review to Roche’s Lunsumio; AstraZeneca to Acquire TeneoTwo; FDA Orphan Drug Designation to PBI-200 Visit Post
19 Comprehensive Assessment of the Leading Companies in the Vaccines Market Visit Post
20 Collagen Matrix FDA 510(k) approval for Fibrillar Collagen Wound Dressing; Roche’s cancer diagnostics ULTRA PLUS system launch; Insightec IDE Approval for Prostate Cancer; JustLight plc. trial of Sunflower Rx for Alzheimer's disease; Thoraflex Hybrid Device Implantation in the United States; FDA 510(k) Clearance for the DABRA 2.0 Catheter Visit Post
21 AstraZeneca’s Imfinzi Shows Positive Results; Novartis Announces Results of Tislelizumab; FDA Grants Orphan Drug Designation to Evorpacept; EU Approves Sanofi’s Xenpozyme; Bayer’s Kerendia Approves in China; FDA Breakthrough Therapy Designation to Talquetamab; FDA Puts Clinical Hold on Sanofi’s Tolebrutinib; FDA Rejects Spero’s Tebipenem Visit Post
22 LumiThera’s US LIGHTSITE III Trial; First Patient Enrolled in Vascular Closure Device Study of Teleflex; Varian’s Flash Technology Clinical Trial, FAST-02; 3Spine’s MOTUS Device; Illumina’s Research Test to Detect Tumor Genome; Acutus Medical's AcQCross Qx System Visit Post
23 Ipsen to Buy Epizyme; BioMarin's Gene Therapy for Hemophilia; AbbVie's Qulipta for Chronic Migraine; FDA Approves Breyanzi for R/R LBCL; NDA Filed for Elacestrant in ER+/HER2- Breast Cancer; EU Approval to Enhertu for Breast Cancer; FDA Approves Novartis’ BRAF-positive Tumor Combination; GSK’s Hepatitis B Vaccine, Bepirovirsen Visit Post
24 CE Mark to Ibex’s Gastric Cancer Detection System; Senseonics’s Eversense E3 Continuous Glucose Monitoring System; NEUSPERA’s NUVELLA SYSTEM; Conformal Medical Initiates CONFORM Pivotal Trial; Meridian Launches New qPCR Master Mixes for Stool Samples; Sentinel Diagnostics Launches SENTiFIT 800 Visit Post
25 How is Nanomedicine Transforming the Dynamics of the Healthcare Industry? Visit Post
26 Biogen terminates ALS Pact with Karyopharm; AbbVie’s Immunological Drug Skyrizi; NICE Backs Astellas’ Oral Therapy Evrenzo; Roche’s Crenezumab Fails in Clinical Trial; FDA Grants Fast Track Designation to Dianhydrogalactitol; Sierra Oncology Submits NDA for Momelotinib Visit Post
27 GSK’s RSV Vaccine Clears Phase III Test in Adults; Roche’s Tecentriq for Adjuvant NSCLC; Owkin Bags $ 180 million from BMS; EU Approves Roche’s Mosunetuzumab; Dostarlimab Elicits Clinical Complete Response in dMMR Rectal Cancer; FDA Backs Bluebird’s CALD Gene Therapy; Takeda’s Dengue Fever Vaccine TAK-003; FDA Approves Dupilumab Visit Post
28 REVIAN RED System Delivers Positive Results, Insulet’s Omnipod Provides Notable Improvement in Type 1 Diabetes, FDA Clearance to Cardio Flow’s FreedomFlow Guidewire; LumiraDx’s Cardiovascular Testing Portfolio; GRAIL-AstraZeneca to Develop Diagnostic Tests; ETHICON Launches Next Generation ECHELON 3000 Stapler Visit Post
29 CG Oncology Teams Up With Merck & BMS; Parse Biosciences Partners With Molecular Diagnostics Korea; Amgen's Olpasiran; Elevar Therapeutics Announces Results of Rivoceranib; FDA Approves GSK’s Measles Vaccine; Sage & Biogen Reveals Postpartum Depression Trial Result Visit Post
30 Bristol-Myers Squibb’s Opdivo Approval; Mirati’s KRAS-inhibitor Adagrasib; J&J and Legend Biotech’s CAR-T Carvykti Approval; Roche’s Glofitamab; Arena Pharma’s Etrasimod Phase 3 Trials; FDA Approves Dermavant’s Vtama; FDA Approves Novartis’ Cell Therapy; NICE Approves Merck’s Keytruda Visit Post
31 Accleus’s Toro-L Interbody Fusion System; Labcorp’s New Test for Skin Cancer; SERA Prognostics’s Preterm Test; Endotronix’s SIRONA 2 Clinical Trial; Anumana’s AI Algorithm to Detect ECG Pulmonary Hypertension; Illumina’s Pan-cancer Companion Diagnostic Visit Post
32 PTC Therapeutics’ Gene Therapy Upstaza; Sanofi and Regeneron’s Dupixent; Bayer CAR-T Collaboration with Atara; FDA Accepts Biohaven’s Zavegepant; AbbVie Files FDA Approval for ABBV-951; Innoviva to Acquire Entasis; FDA Orphan Drug Designation to XMT-2056; FDA Approves Azacitidine for Juvenile Myelomonocytic Leukemia Visit Post
33 AstraZeneca’s Farxiga; Incyte’s Jakavi; FDA Fast Track Status to HM43239 for R/R AML; Idorsia’s Insomnia Drug Quviviq; EU Approves Kymirah For Follicular Lymphoma; Perrigo Acquires HRA Pharma; Janssen Submits Marketing Authorisation Application to EMA Visit Post
34 GE and Medtronic's Collaboration; Vivalink's Multi-Vital Blood Pressure Patch; Foldax's TRIA Biopolymer Surgical Aortic Heart Valve; Vektor Medical's vMap Clinical Validation Study; iSono's ATUS System; Mirvie's Test to Identify Risk of Preeclampsia Visit Post
35 VBL Therapeutics’ VB-111 (ofranergene obadenovec); BMS’s mavacamten (Camzyos); Merck’s KEYTRUDA; AstraZeneca and Daiichi’s Enhertu; Pfizer/Biohaven’s VYDURA (rimegepant); AstraZeneca’s Ultomiris; Supernus’s Viloxazine (Qlebree); AbbVie’s Rinvoq Visit Post
36 Coherus Biosciences’ Toripalimab; Keymed’s CMG901; Biogen Alzheimer’s Drug Aduhelm; Vicore’s Digital Therapeutics Study; Cassiopea’s Acne Treatment Winlevi; Samsung Biologics Acquires Samsung Bioepis; Roche’s Giredestrant; Ashai Kasei Acquires Bionova Visit Post
37 Rise In Bispecific Antibodies Utilization As Antibody Therapeutics Visit Post
38 Top 12 Most Expensive Drugs in the US Healthcare Market Visit Post
39 GSK Acquires Sierra Oncology; BriaCell’s Targeted Breast Cancer Immunotherapy; Merck’s Tepmetko; Gilead’s Magrolimab for MDS and AML; Eli Lilly’s Retevmo; Merck’s Pneumococcal Vaccine; FDA Approves Bevacizumab Biosimilar; Halozyme to Acquire Antares Pharma Visit Post
40 AACR 2022: Novartis shifting focus towards directly targeting KRASG12c after disappointment from SHP2 inhibitor, TNO155. Visit Post
41 AACR 2022 updates, recent disappointment, deals and collaboration of TIGIT immunotherapies Visit Post
42 Alcon’s Dry Eye Treatment Device; I-VASC Secures Series A Funding; Paige’s AI Medical Device Software; TRUVIC’s Prodigy Thrombectomy System; Alucent’s Natural Vascular Scaffolding Technology; Guardant Presents Data Supporting Efficacy of Blood Test in Detecting Multiple Cancers Visit Post
43 BioXcel’s Agitation Drug Igalmi; FDA Approves Cysteine Hydrochloride Injection; Gilead’s Trodelvy; Alembic Pharma’s Topical Anesthetic Cream; Pfizer Acquires ReViral; Telix Buys Lilly's Failed Cancer Drug Lartruvo Visit Post
44 Precigen's PRGN-3006; Yescarta Approved as a First CAR T-cell Therapy for R/R LBCL; Biogen & Ionis’ BIIB078; Nobelpharma's HYFTOR (sirolimus topical gel) 0.2%; Cerevance Parkinson’s Drug; Sanofi & Regeneron’s Dupixent; Clovis’s Rubraca for Ovarian Cancer; Immunocore Eye Cancer Cell Therapy Approval Visit Post
45 LAG 3: A Promising Next Generation Cancer Immunotherapy Visit Post
46 Ypsomed-CamDiab's Collaboration; Vela Diagnostics’s NGS-Based Pan-Cancer Panels; Fresenius's SMOFlipid Lipid Injectable Emulsion; Sientra Gained Regulatory Nod to Market Breast Implants; Synchron’s Endovascular BCI Stentrode Device; HLT’s TAVR Clinical Studies Visit Post
47 Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022 Visit Post
48 Sanofi’s Rare Disease Drug Xenpozyme' Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB's FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval Visit Post
49 Bristol Myers’ Opdivo combo Opdualag for Melanoma; Biogen’s Aduhelm; Marinus’ Ztalmy for CDKL-5 Deficiency Disorder; Merck’s Keytruda + Lynparza; Vitaris’s Breyna; Moderna’s Second COVID-19 Booster Shot; Takeda’s Exkivity; BMS’s First LAG-3 Checkpoint Inhibitor Visit Post
50 Exploring the Metastatic Castration-Sensitive Prostate Cancer Market Landscape Visit Post
51 Can Cannabinoids be an Effective Medicinal Substance? Visit Post
52 AstraZeneca and Merck’s Lynparza; Venatorx’s cefepime-taniborbactam; AbbVie’s Qulipta; AstraZeneca’s IL-5 inhibitor Fasenra; Sandoz Acquires Coalesce; Incyte’s Opxelura; Bayer’s Nubeqa; NICE Rejects Keytruda Plus Chemotherapy Visit Post
53 Small Cell Lung Cancer Treatment Market Propels Due to Extremely Robust Pipeline Visit Post
54 Lilly & Boehringer’s Jardiance; BMS Secures a Neoadjuvant Market for Opdivo; Amgen & NHS Signs a Deal; Roche’s Alzheimer Drug gantenerumab; Pfizer’s RSV Vaccine; Civica’s Insulin Biosimilars; Eli Lilly & Incyte’s JAK inhibitor Olumiant; Natco Pharma Launches Revlimid Generic Visit Post
55 Top Five Liquid Biopsy Companies Impacting Cancer Diagnostics Market from 2021 to 2026 Visit Post
56 Data readout of potential ADCs: Enhertu gears up for Urothelial Carcinoma Market now Visit Post
57 PARP inhibitors in Urothelial carcinoma (UC): Hit or miss? Visit Post
58 GSK’s Covifenz; Idorsia's Quviviq; GSK’s ZEJULA; EMA Expands its Nod for BMS, Eli Lilly, and Novartis Drugs; Cantex Secures Global Licence to Develop Azeliragon; Biocon Acquires Viatris’ Biosimilar Business Visit Post
59 Osteosarcoma vs Ewing sarcoma Visit Post
60 ASCO GU 2022: Renal Cell Carcinoma Highlights Visit Post
61 Seagen/Astellas plans to expand their Antibody Drug Conjugate (ADC), Padcev in additional bladder cancer settings? Visit Post
62 With early-stage data, Chimeric antigen receptor T cell (CART) finding its way towards entering Prostate and Kidney Cancer market Visit Post
63 Early but strong clinical data of Arvinas’s ARV-110 in Men with mCRPC that support a potential path to accelerated approval Visit Post
64 Motus GI’s Pure-Vu EVS System; EvoEndo’s Single-Use Unsedated TNE System; Orthofix’s OpusTM BA; Invitae’s CE-IVD Cancer Testing Kits; PolyActiva’s PA5108 Ocular Implant; Ra Medical’s DABRA excimer laser system Visit Post
65 Sandoz’s Generic Revlimid; Agios' Pyrukynd; Organon Announces 4Q & Full-year Earnings Report; BMS’ CAR-T Drug Breyanzi; Sanofi & Regeneron’s Dupixent Trial; AZ & Daiichi’s Drug Enhertu; Bayer’s Drug Kerendia; Lilly Releases Mirikizumab Data Visit Post
66 Nubeqa (darolutamide) increases overall survival in men with mCSPC/HSPC when added to androgen-deprivation treatment (ADT) with docetaxel: ARASENS phase III study Visit Post
67 B7-H3, an emerging immune checkpoint molecule in metastatic CRPC and other cancers Visit Post
68 PARP inhibitors making inroads towards the first line metastatic Castrate-resistant prostate cancer (CRPC) market soon? Visit Post
69 Gastroenteropancreatic Neuroendocrine Tumours Market To Gain Substantial Momentum With Entrance of Novel Therapies Visit Post
70 Össur Launches POWER KNEE; DePuy Synthes Acquires CrossRoads Extremity Systems; Myomo’s MyoPro; Accuray’s TomoTherapy System; Theradaptive’s Spinal Fusion Implant; Senseonics’s Eversense E3 CGM System Visit Post
71 Pfizer & Lilly's JAK Inhibitors Drug; FDA Approves Lilly's Bebtelovimab; GSK's Benlysta; Daewon’s Non-steroidal Anti-inflammatory Drug; Lilly & Innovent’s Lung Cancer Drug; Bayer’s Asundexian Visit Post
72 Mapping the Biggest Pharmaceutical Companies by Continents Visit Post
73 Stryker’s Tornier Shoulder Arthroplasty; Genesis Acquires JC Medical; FDA Clearance to Single-Use Gastroscope; BioCardia’s CardiAMP Cell Therapy System; Abbott’s Dual-Chamber Leadless Pacemaker; atHeart’s ASCENT ASD U.S. IDE Visit Post
74 Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment Visit Post
75 Biogen's Aduhelm; FDA Approves Sanofi's Enjaymo; NHS & Orchard Signs a Deal; Bristol’s Breyanzi & Abecma; Pharming’s Leniolisib; Eli Lilly’s Verzenio Trial; UCB’ Zilucoplan Trials Result; Eli Lilly’s Alzheimer's Drug Donanemab Visit Post
76 Widespread Usage of HPV Vaccine Reduces Cervical Cancers and Precancers Visit Post
77 Insulet’s Omnipod 5 Automated Insulin Delivery System; Alivecor's KardiaMobile Card; BD Board Approved the Spinoff of embecta; Medtronic’s Hugo Surgery Robot; Artivion’s On-X® Mitral Heart Valve PROACT; OmnySense's Smart Thermometer Clinical Trial Visit Post
78 Immunocore’s Kimmtrak; Samsung Acquires Biogen's Biosimilar Unit; Novavax’s COVID-19 Vaccine; CHMP Approves Dupixent (dupilumab); Glenmark’s High Blood Pressure Treatment; Roche’s Faricimab; GBT’s Voxelotor Visit Post
79 Merck’s Gefapixant; Pfizer's Somatrogon; Gilead’s Viklury; AbbVie’s Skyrizi; Gilead's Zydelig Approvals; Lantern’s LP-184; Polpharma to Acquire Advent Visit Post
80 Algernon’s NP-120 (ifenprodil); Pieris's cinrebafusp alfa (PRS-343) clinical trial; Gaumard Scientific’s multidisciplinary patient simulator HAL S5301; Hekka Labs’s decentralized healthcare ecosystem Visit Post
81 Most Promising Oncological Drugs Expected to Launch in 2022 Visit Post
82 Insights into the Evolving Landscape of Antibody-Drug Conjugate (ADC) & the Key Companies in the Segment Visit Post
83 Noxxon’s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent’s clinical trails for NVL-520; Stryker acquires Vocera Communications Visit Post
84 Novel and Emerging Metastatic Colorectal Cancer Treatment Drugs Anticipated to Change Market Dynamics Visit Post
85 Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021 Visit Post
86 Accutar's Phase I clinical trial for AC0176; Bio-Thera's cancer drug, BAT6005; Nykode's Covid-19 vaccine trial; Heat Biologics acquires Elusys Visit Post
87 Biogen-Eisai's Aduhelm; Quidel acquires Ortho Clinical Diagnostics; Accutar Biotechnology’s AC0176; Boehringer’s Spesolimab Visit Post
88 Major Highlights of Diffuse Large B-cell Lymphoma/ Large B-cell lymphoma (LBCL) in ASH 2021 Visit Post
89 Analyzing the Key Trends Driving the Biosimilar Market Growth Visit Post
90 Edwards’ Sapien 3 with Alterra Prestent; Koios Medical’s breast, thyroid cancer-spotting AI; Lineage Collaborates with Genentech; Novartis, BeiGene ink deal Visit Post
91 Insights into some of the Biosimilar Drugs that are approved and launched in 2021 Visit Post
92 Pfizer to acquire Arena Pharma; Takeda's 'Wave 2' multiple myeloma med data; Novartis's next-gen CAR-Ts clinical data; Roche unveils Avenio system Visit Post
93 CAR-T Cell Therapy aka Miraculous Technology: Mapping the Market, Approved Therapies, Competitive Landscape and Impact of COVID-19 Visit Post
94 Major Highlights of ASH 2021 Annual Meeting: Stay abreast of the fresh developments!! Visit Post
95 Boston Scientific's MODULAR CRM System; Restore Medical's ContraBand clinical trial result; BD acquires Venclose; Roche differentiates mutations in Omicron; Linus's StrandDx-ASD; HelioLiver launches liquid biopsy test Visit Post
96 Aslan Pharma - IQVIA collaboration; Reata's kidney drug bardoxolone; Alzheimer’s Disease treatment update; Recordati to acquire EUSA Visit Post
97 T-cell Immunoglobulin and ITIM domain (TIGIT) Inhibitor: An Insight into the Pipeline Development Activities, Major Collaborations, and Advancements Visit Post
98 Analyzing the Growth of the Biosimilar Market Through Years Visit Post
99 GE Healthcare-Optellum's collaboration; Ocugen’s Covid-19 vaccine trial; Blueprint to acquire Lengo Therapeutics; Therapixel's Mammoscreen Visit Post
100 Diverse Pipeline Therapies to Glide the Follicular Lymphoma Treatment Market Visit Post
101 AstraZeneca-Moderna's AZD8601 VEGF-A mRNA Trial; Wision AI gets CE Mark approval; Getinge acquires Verrix; LumiThera buys Diopsys Visit Post
102 Alcon to acquire Ivantis; Philips to takeover Cardiologs; Flunked cancer drug progresses in I-O in pancreatic cancer models; Indigo system CAT RX catheter meets primary endpoint in trial Visit Post
103 An in-depth Assessment of the Top Drugs Launched by Leading Global Companies in the First Half of 2021 (H1) Visit Post
104 Ocular Therapeutix’s insert fails in phase 2; Click Therapeutics raises $52M funding; Roche introduces AVENIO Tumour Tissue CGP Kit; Blue Wolf Capital to acquire CIVCO Radiotherapy Visit Post
105 Hologic to acquire Bolder Surgical; Breakthrough Device Designation to Biological Dynamics; Luminopia declares FDA approval; HistoSonics secures Breakthrough Device Designation; Phillips-Medisize expands worldwide; PolyNovo launches NovoSorb BTM tech Visit Post
106 Brickell to Submit New Drug Application to FDA; Twin Health Raises $140M; BMS' Deucravacitinib; Lando Biopharma’s LABP-104 gets Approval; NIH Grant of $ 3 M to Amydis; FDA Grant to GenSight’ GS030 Visit Post
107 Bone Metastasis Market: A Debilitating Consequence for Many Tumors Visit Post
108 Pfizer tightens DMD trial criteria over safety concerns; Kytopen raises $30M; Eli Lilly taps Reify's Care Access; Vensana Capital raises $325M Visit Post
109 RETINA-AI Health declares positive results; Medtronic's Hugo robotic-assisted surgery system; Boston Scientific acquires Devoro Medical; Paige obtains first-ever FDA approval Visit Post
110 Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biotech 858 Therapeutics inks $60M Series A; Novartis acquires Arctos Medical Visit Post
111 Follicular Lymphoma Market Size Anticipates Growth as the Key Companies Explores Novel Therapeutics Assets Visit Post
112 FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises Visit Post
113 Assessing the Opportunities and Challenges in the Oncology Segment Visit Post
114 Evaluating the Present and Future Oncology Market Outlook With Valued Research and Analysis Visit Post
115 ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System Visit Post
116 Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer Visit Post
117 Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm Visit Post
118 Abiomed’s Impella ECP; Helius’s PoNS Device; Smart Meter’s iGlucose BGM; XACT’s CT-Guided Percutaneous Procedures; BD’s Veritor At-Home COVID-19 Test; Delfi’s Liquid Biopsy Visit Post
119 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
120 Merck’s Keytruda Approval; Abbvie’s Venetoclax; Aprea's Eprenetapopt; CRL to Incyte’s Retifanlimab; Keytruda/Lenvima for Endometrial Cancer Visit Post
121 Evolving Landscape for Rare Biomarkers in Non-Small Cell Lung Cancer Visit Post
122 MedTech Wrap Up Visit Post
123 Key Pharma Companies Expanding their Arm in the Skin Cancer Segment Visit Post
124 Unity's advanced vascular eye disease trial; Rallybio raises $100 M; Sanofi bets over $1B for Eureka's candidate; Lilly invests in MiNA; Visit Post
125 Arrowhead's ARO-ENaC Clinical Trial; Sartorius Acquires Stake in CellGenix; AGC Biologics's Cell & Gene Therapy; Sirnaomics Secures $105 Million Visit Post
126 Horizon/ Arrowhead Deal; Dr Reddy's Lab’s Drug US Launch; Targovax’s ONCOS-102; RedHill's Oral Opaganib in COVID-19 Visit Post
127 Mallinckrodt earns FDA nod for skin therapy; RayzeBio secures $108M; VectorY raises $38M; Umoja banks $210M Visit Post
128 Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M Visit Post
129 Diagnosis Delays, Ineffective Treatment Options Plaque the Bone Cancer Market Growth Visit Post
130 Amgen a leader in Undruggable Lung Cancer; Verrica's Skin Disease Drug Delays; Fennec's Faith in its Chemotherapy-Induced Hearing Loss Drug; Nexturn Bio's Acquisition of RosVivo Visit Post
131 TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug Visit Post
132 InnoCare's Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab Visit Post
133 Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids Visit Post
134 Glioblastoma Multiforme: Advancements in the Treatment Paradigm of the Malignant Condition Visit Post
135 Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med Visit Post
136 Adagio Raises $336 M; Lyndra's Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy Visit Post
137 Ewing Sarcoma: Key Companies and Emerging Therapies in the Landscape Visit Post
138 Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO Visit Post
139 Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities Visit Post
140 Limited Therapeutics Options and A Weak Pipeline: What Lies Ahead in the Cancer Anorexia Market? Visit Post
141 Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application Visit Post
142 A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers Visit Post
143 Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels Visit Post
144 Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche's Tecentriq Results in NSCLC Visit Post
145 Navigating Through the Treatment Market Landscape of Head and Neck Cancers Visit Post
146 GBT strikes a deal with Sanofi; Lilly's IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy Visit Post
147 Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta's Kimyrsa Visit Post
148 Overwhelming success of Gilead/Kite's Yescarta; Ridgeback/ Merck in the COVID-19 game; AnaptysBio's antibody-drug failure; Roche discards Tecentriq for bladder cancer Visit Post
149 Rare Cancer Market: A Global Crusade on what is a ‘less common cancer’? Visit Post
150 Evotec, Chinook Teams Up for CKD Therapy; HitGen & UPPTHERA in Drug Delivery Research; Artiva's $120 M Coup of NK Cell Therapy; Junshi & AZ with Toripalimab in China Visit Post
151 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
152 Clover biopharmaceuticals raises $230 M; BrainStorm after ALS; BARDA grants $5.65 M LightDeck for SARS-CoV-2 antigen test; Libtayo for first-line advanced NSCLC subset Visit Post
153 Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval Visit Post
154 Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda's Maribavir; Astellas/Seagen Padcev Visit Post
155 Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Visit Post
156 Progeria: The Rarest Case of Premature Ageing Visit Post
157 Deerfield/ Dana-Farber’s USD 130 Million Cancer Research Deal; FDA-Approval to BMS’ Breyanzi & TG Therapeutics’ Ukoniq; EU Marketing Rights for ViiV Healthcare’s Rukobia Visit Post
158 Fake News In The Healthcare Sector: A Misinformation Crisis In The Era Of Digitalization Visit Post
159 Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone Visit Post
160 Nirogy rises with $16.5M; Iterum presents a new drug application to FDA; Gut Bacteria proffer insight into molecules protection; TScan adds another $100M for cancer trials Visit Post
161 Unshackling TP53 in leukaemia with a novel combo; Merus receives funds for cancer research pact; Vera Therapeutics bags $80M; Gritstone appends COVID-19 to the pipeline. Visit Post
162 Biohaven's Troriluzole Failure; Daiichi/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro Visit Post
163 Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics Visit Post
164 Medical Tourism: Road to Affordable and Quality Medical Care Visit Post
165 Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results Visit Post
166 Unmet Needs and Emerging Trends in the Acute Respiratory Distress Syndrome Market Landscape Visit Post
167 Improving cancer immunotherapy; Senseonics' Eversense delayed; FDA acknowledges Alkermes' Resubmission; 3D breast ultrasound improves diagnosis Visit Post
168 NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche's bispecific matches Eylea; Research Updates in Leukemia, solid tumors Visit Post
169 Agios' cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial Visit Post
170 13 of the most commonly asked questions about Glioblastoma multiforme, Answered Visit Post
171 Mitochondria destruction for Cancer Treatment; Atsena raises USD 55 Million financings; Novartis and Cadent Therapeutics collaboration; Neuron23’s strategy to tackle CNS disorders Visit Post
172 Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well? Visit Post
173 AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra's X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3 Visit Post
174 KaliVir, Astellas licensing deal; AbCellera's IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH Visit Post
175 Roche's quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study Visit Post
176 BASE10 Collaboration; Advaxis Public offerings; Takeda's CABOMETYX Japan approval; TheraPharm Acquisition Visit Post
177 Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant's vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic Visit Post
178 Biliary Tract Cancer: Emerging Players in the Market Transforming the Treatment Landscape Visit Post
179 Pfizer succeeds COVID-19 vaccine safety milestone; Sanofi snags speedy review for BTK drug; Autoimmune diseases research updates; Elevation Oncology secures $65 M Visit Post
180 Lung Cancer and its Increasing Global Burden Visit Post
181 Albireo Pharma's PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna's Weapon Against COVID; Gilead & Novo Nordisk's Cocktail Therapy for NASH Visit Post
182 Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone's deal for checkpoint inhibitors Visit Post
183 Bayer eyes AskBio’s Gene Therapies; Novartis' Iptacopan; Forma's IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic Visit Post
184 7 Most Common Myths About Breast Cancer Demystified Visit Post
185 Key Facts To Know About Triple-Negative Breast Cancer In The Breast Cancer Awareness Month Visit Post
186 Breast Cancer: Understand your breasts, recognize the symptoms Visit Post
187 Market Drivers and Barriers That Will Shape The NMIBC Market In The Next Ten Years Visit Post
188 Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma Visit Post
189 How do we curb the Opioid Epidemic? Visit Post
190 Key Companies To Keep an Eye on for Pipeline Therapies in Osteosarcoma Market in the Next Decade Visit Post
191 Pitfalls of Current Osteosarcoma Treatment Approaches Visit Post
192 Brain's immune cells research update; Moderna's COVID-19 vaccine; Pfizer funnels $200 M into CStone; Myovant's relugolix falls short in metastatic prostate cancer; Alnylam's lumasiran phase 3 result Visit Post
193 Conditions Medical Marijuana is Anticipated to be Prescribed in the Offing Visit Post
194 Glioblastoma Multiforme Market: Emerging Pipeline Therapies To Keep A Keen Eye On Visit Post
195 Huge Unmet Needs in the Glioblastoma Multiforme Treatment Market Driving the Market Size Growth Visit Post
196 Samsung/AZ Deal; Gyroscope’s Dry AMD Gene Therapy; Inflazome's Buyout; Abbott’s MitraClip4 EU Approval; Grail Buybacks Visit Post
197 Cervical Cancer Market Has A Lot Going On Under The Hood Visit Post
198 Lilly's COVID-19 antibody reduces hospitalization rate; Tiny biologic drug to combat COVID-19; Aziyo Biologics files for $57.5 M IPO; BMS exercises option on Obsidian's CD40L cell therapy Visit Post
199 While AZ resumes its COVID-19 vaccine trial in the UK; Merck and Gilead are busy making sizeable Breast cancer deals Visit Post
200 Preventing Cervical Cancer Through Screening And HPV Vaccines Visit Post
201 Pfizer-BioNTech COVID-19 vaccine trials; OncoImmune raises $56 M; Recursion Pharma nets $239 M; Breast cancer research updates Visit Post
202 Multiple Myeloma: An Incurable B-cell malignancy and A Vicious Cycle of Relapse Visit Post
203 Amylyx's neuron-protecting drug slows ALS decline; Antisense drugs could help fight ALS and dementia; CAR-T research updates; Orca and Lyell announces research partnership Visit Post
204 Healthcare Delivery System: What lies in the future? Visit Post
205 Moderna's COVID-19 vaccine trial; Freenome secures $270 M; CRISPR treats obesity in mice; Breast cancer research updates Visit Post
206 Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis Visit Post
207 MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic's IMU-838 promising results Visit Post
208 Enough Of Wasting Away From Cancer: Companies Gear Up To Tackle Cachexia Visit Post
209 AZ, Daiichi inks an oncology deal; Moderna begins Phase III trial of its COVID-19 vaccine; No good news for Solid's DMD gene therapy trial Visit Post
210 Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai's Collaboration; A new study on averting heart attack Visit Post
211 Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update Visit Post
212 Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates Visit Post
213 Small Cell Lung Cancer Market Booms with an Influx of Companies and Robust Pipeline Visit Post
214 Top 5 Cancers Creating Major Challenge To The Global Healthcare System Visit Post
215 Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab's result; Orca raises $192M Visit Post
216 Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL Visit Post
217 One of the leading causes of blindness, and a sight-threatening disease, Uveitis, now has novel treatment approaches in its pipeline Visit Post
218 Precision Medicine: An emerging approach to conventional treatment Visit Post
219 Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ's anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost Visit Post
220 Altering the course of Ovarian cancer with emerging therapies in the horizon Visit Post
221 Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses Visit Post
222 Changing the Paradigm of Cancer: Neoantigen based Personalized Cancer Therapeutic Vaccines Visit Post
223 Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19 Visit Post
224 Soft Tissue Sarcoma Market size to increase with a CAGR of 6.47% – Emerging therapies and Increasing Incidence form major market drivers Visit Post
225 JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19 Visit Post
226 Soft Tissue Sarcoma Treatment Market: Present treatment approaches and Unmet Needs Visit Post
227 Soft Tissue Sarcoma: A rare malignancy Visit Post
228 Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust Visit Post
229 J&J collaborates with BARDA; Virus kills pancreatic cancer cells; ALX raises USD 105 million for CD47 drug Visit Post
230 Good news for Kite’s KTE-X19, and Aquestive’s Libervant; and a commercialization deal between ReForm Biologics, MilliporeSigma Visit Post
231 First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed's shares Soares Visit Post
232 Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102 Visit Post
233 Malignant Pleural Mesothelioma Upcoming Therapies Visit Post
234 Malignant pleural mesothelioma market: Elusive treatment approaches and Poor diagnosis Visit Post
235 Novome raises USD 33M, Buyout of Bioniz, Adagene raises USD 69M Visit Post
236 Marijuana as a treatment approach Visit Post
237 Nunaps raises USD 4.2M; Arcutis files for USD 100M IPO Visit Post
238 GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3 Visit Post
239 Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval Visit Post
240 Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition Visit Post
241 Acquisition of ArQule; Synthorx; and Zentalis nabs a raise Visit Post
242 Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval Visit Post
243 Novartis buys Medicines Co. for USD 9.7 Billion Visit Post
244 Metastatic Pancreatic Cancer Market Size: Emerging therapies, Unmet needs and Forecast analysis Visit Post
245 Non-small cell lung cancer emerging therapies Visit Post
246 AstraZeneca tops the first Pharma Invention Index; Amgen to buy 20.5% stake in a Chinese pharmaceutical, BeiGene; Ascentage, Henlius collaborates to develop a Combination therapy Visit Post
247 Non-Small Cell Lung Cancer Market: Treatments and Market Forecast Visit Post
248 AZ announces positive results for durvalumab and tremelimumab; FDA nods to extend LILETTA’s use to prevent pregnancy; Gilead, Glympse Bio teams up to advance NASH clinical development Visit Post
249 Refractory Metastatic Melanoma Market Visit Post
250 Metastatic HER2-Positive Breast Cancer Infographic Visit Post
251 Rapt Therapeutics files IPO; Novartis stakes $80M for NASH Visit Post
252 New Therapeutic advances that have shifted the Breast cancer market scenario Visit Post
253 HR-positive/ HER2-negative Breast Cancer Market Insights: Upcoming Therapies and Market Analysis Visit Post
254 Roche’s Tecentriq combo proves effective in Bladder cancer Visit Post
255 STipe raises USD 22M; FDA approves Darzalex for multiple myeloma Visit Post
256 Flagship Pioneering launches Omega Therapeutics; EU nod to Vitrakvi; Bluebird Bio reveals positive results of Starbeam clinical trial Visit Post
257 Fujifilm acquires global rights to Cynata's novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop's digital diabetes platform Visit Post
258 AlivaMab collaborates with Janssen for antibody discovery; Lundbeck acquires Alder BioPharmaceutical; Helsinn and Mundipharma announce China approval of Akynzeo Visit Post
259 How HR+/ HER2-Breast Cancer emerging drugs will transform the market? Visit Post
260 Global HR+/ HER2- Breast Cancer Market Scenario Visit Post
261 Genenta Sciences raises USD 14.54M; GSK announces to buy Sitari Pharmaceuticals; Mallinckrodt to Sell BioVectra for USD 25M; Lexicon to receive USD 260M from terminated diabetes partnership  Visit Post
262 Daiichi Sankyo fuels commercialization of DS-8201 in Japan; Roivant Sciences transfers its biotech stake for USD 3 Billion; FDA, EMA accepts marketing of Allergan’s abicipar Visit Post
263 Metastatic HER2-Positive Breast Cancer Visit Post
264 Driving factors boosting the Hepatocellular Carcinoma Market Visit Post
265 Helsinn out licenses Pracinostat in South America Visit Post
266 HiFiBio raises USD 67 M; FDA drafts new guidelines for Breast cancer trials; Harbour BioMed teams up with Pharmaceutical Product Development Visit Post
267 What to expect in the Coming Years for Hairy Cell Leukemia Therapy landscape? Visit Post
268 Imfinzi fails. What’s next in Non-small cell lung cancers Market Scenario? Visit Post
269 Juvenescence nets USD 100M; Sarepta DMD drug faces rejection Visit Post
270 Chemotherapy-Induced Peripheral Neuropathy Market Trends Visit Post
271 Turalio gets FDA approval; Sosei Heptares, Takeda forms an R&D pact Visit Post
272 FDA approval for Nubeqa; Biodesix, Immodulon collaborates on Cancer treatment; Cancer asset rights to Alligator Bioscience Visit Post
273 CHPM’s positive approval for 13 Medicines; NICE approval for AstraZeneca’s Olaparib; Exact Sciences to buy Genomic Health Visit Post
274 Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M; FDA approval for Ruxience for leukaemia Visit Post
275 FDA approves Lyrica; CRH Medical purchase Crystal River Anesthesia Visit Post
276 Osivax raises USD 9M; Smyraf launched; Revolution secures USD 100M Visit Post
277 Cutaneous T-cell lymphoma Market Outlook Visit Post
278 EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline Visit Post
279 FDA's approval to Pfizer’s Zirabev; Launch of Century Therapeutics; Imbruvica's recommendation from CHMP Visit Post
280 Zejula's priority review; Erytech Pharma's new facility; good news for Krystal Visit Post
281 The Business Cocktail Visit Post
282 Notizia Visit Post
283 World Brain Tumor Day Visit Post
284 The Business Cocktail Visit Post
285 Notizia Visit Post
286 Global Neuroendocrine Tumor Market Outlook Visit Post
288 The Business Cocktail Visit Post
289 Notizia Visit Post
290 The Business Cocktail Visit Post
291 Ginkgo to buy mining platform; Vertex, Kymera collaborate; ArcherDX nets $60M; Bayer to invest $150M Visit Post
292 AstraZeneca-Daiichi’s results; Novartis remunerates; Pfizer to acquire Therachon; Gilead & Goldfinch Bio collaboration Visit Post
293 World Ovarian Cancer Day | 2019 Visit Post
294 Notizia Visit Post
295 Ovarian Cancer Treatment Drugs and Unmet Needs Visit Post
296 The Business Cocktail Visit Post
297 Notizia Visit Post
298 Can commoners afford to spend million dollars on GENE Therapy? Visit Post
299 Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen; Insitro lands a deal Visit Post
300 Notizia Visit Post
301 Gene Therapy in Oncology: Innovation to Commercialization Visit Post
302 Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix; EdiGENE raises $15M; Antengene announces its expansion Visit Post
303 The promising Pipeline for Gene Therapy In Oncology Visit Post
304 Notizia Visit Post
305 Notizia Visit Post
306 Multiple Myeloma Day Visit Post
307 The changing landscape of Multiple Myeloma therapies market Visit Post
308 Notizia Visit Post
309 ColdZyme inactivates viruses; Med for rare genetic disease; Common oral bacteria accelerate Colon cancer; CEPI and CureVac to develop an mRNA vaccine; Celastrol’s effectiveness Visit Post
310 A helping hand in treatment of CRC Visit Post
311 What is Cholangiocarcinoma (CCA)? Visit Post
312 Notizia Visit Post
313 Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets Visit Post
314 Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways Visit Post
315 Genentech remunerates Xencor; XPrize upraises fund; GSK gambles Visit Post
316 Neuroendocrine Tumors (NETs) Visit Post
317 Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal Visit Post
318 Biodesix collaborates with MRM; Avoiding flu with an antibody; Soliris clears trial Visit Post
319 Molecular Profiling Could Help in Early Lung Cancer Detection: Study Visit Post
320 BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M Visit Post
321 Notizia Visit Post
322 Cervical cancer Visit Post
323 Virtual Reality Maps Helps Doctors Understand Cancer Tumor Structure Visit Post
324 Highly mutated cancers respond better to immune therapy Visit Post
325 Notizia Visit Post
326 Triple Negative Breast Cancer Responds to TINAGL Therapy Visit Post
327 Apollomics raises; Pear Therapeutics raises $64M; Lilly to acquire Loxo Visit Post
328 Sage’s drug meets phase 3; Blocking 2 key pathways help in tackling TNBC; FDA clears Paragonix; FDA gives a nod Visit Post
329 Machine Learning Models to Help Predicting Cancer Symptoms, Plan Treatment Visit Post
330 Cervical cancer: What you need to know Visit Post
331 HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer’s; Bristol-Myers, H3 Biomedicine discover RNA splicing Visit Post
332 66 Year Ohio Woman Becomes Cancer Free, Thanks to CAR T Cell Therapy Visit Post
333 Now, Artificial Intelligence to Accurately Identify Cancer Cells Visit Post
334 Gold Nanoparticles May Soon Treat Prostate Cancer Visit Post
335 Cancer Cells Trick Body’s Immunity to Survive against Treatment Visit Post
336 Notizia Visit Post
337 Scientists Now Target Attacking Evolution Process of Cancer Cells Visit Post
338 Chemotherapy as a treatment for Cancer?  Visit Post
339 Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal; Boston Scientific remunerates Visit Post
340 Actinic Keratosis – A Warning Sign for Potential Skin Cancer Visit Post
341 Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal Visit Post
342 Notizia Visit Post
343 Virus, the Cancer Therapy of the Future Visit Post
344 Triple Negative Breast Cancer Visit Post
345 Gordon and Betty Moore Foundation gives $85M; Omeicos raises; Sanofi signs deal; Lilly grabs Visit Post
346 FDA approves Zulresso; Pfizer receives approval; Novartis relinquishes Rituxan Visit Post
347 Lung Cancer Infographic Visit Post
348 150 Year Old Drug Indicates Potential of Future Cancer Therapy Visit Post
349 The risk of solid cancer after chemotherapy Visit Post
350 Notizia Visit Post
352 Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug Visit Post
353 Notizia Visit Post
354 Is Gene Therapy the Next Cancer Treatment Revolution?  Visit Post
355 Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray Visit Post
356 Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand Visit Post
357 The novel therapy for brain cancer treatments Visit Post
358 Precautions for Breast Cancer Visit Post
359 Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner Visit Post
361 Companion Diagnostics Visit Post
362 Notizia Visit Post
363 Researchers Turn towards Light to Solve Lung Cancer Puzzle Visit Post
364 Epic Sciences garners; Tvardi gets financing; Galera raises; Fund for cancer research Visit Post
365 Snippet Visit Post
366 Biologic Parallel – A Perky Future Ahead Visit Post
367 Notizia Visit Post
368 Pancreatic Cancer Treatment to Stride Beyond Chemotherapy Visit Post
369 Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M Visit Post
370 Snippet Visit Post
371 Notizia Visit Post
372 Neuroendocrine tumors (NETs): The complex group of tumors Visit Post
373 Now, Nanoparticles for Cancer Treatment Visit Post
374 4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker Visit Post
375 Commercial Visit Post
376 Clinical Visit Post
377 AbbVie Receives Approval; Kymriah Approved; Shire Gets USFDA Approval; NICE Rejects; Bristol-Myers Squibb’s Opdivo; Eisai and Merck Get USFDA Approval Visit Post
378 Outset Medical captures; Wright Medical Group to takeover Cartiva; Y-mAbs Therapeutics prepares for IPO; Biotech boom remunerates analysts Visit Post
379 China Preparing for Pharma Big Bang: Is this Alarm Bell for US, Euro Pharma Giants? Visit Post
380 Japan Manages to Stand Apart from Global Hepato Cellular Carcinoma Crowd Visit Post
381 AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal Visit Post
382 Snippet Visit Post
383 Kalydeco got approved; Opdivo for SCLC; FDA approved for pain relief; GC4419 obviates Visit Post
385 Personalized Medicine Approach: An Upholding Paradigm for a Promising and futuristic Patient Centric Health Care Visit Post
386 Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup Visit Post
387 Progenics got FDA Approval; Curcumin to cancer cells Visit Post
388 Sutro nets $85.4M; HiFiBiO pens Takeda R&D collaboration Visit Post
389 Snippet : Acute lymphoblastic leukemia Visit Post
390 Business Cocktail Visit Post
391 Commercial Outcomes - Novartis Visit Post
392 Oncology Highlights - 30/07/2018 Visit Post
393 Predicting risk of Acute Myeloid Leukemia (AML) in healthy individuals Visit Post
394 NF-κB Inhibitors- A Promising Future Visit Post
395 Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation Visit Post
396 Business Cocktail Visit Post
397 Hematopoietic Stem Cell Transplantation Visit Post
398 Takeda buys Shire in a deal worth USD 62 billion Visit Post
399 Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod Visit Post
400 Horizon Discovery declines Abcam’s USD 367 million takeover bid Visit Post
401 Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients Visit Post
402 STAT INHIBITORS- Highly active Pipeline Visit Post
403 Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs Visit Post
404 Takeda acquisition on Shire raises its share by 25 percent Visit Post
405 Business Cocktail Visit Post
406 Business Cocktail Visit Post
407 New method for classification of CNS tumors Visit Post
408 Notizia Visit Post
409 Notizia Visit Post
410 The Business Cocktail : Latest Pharma deals Visit Post
411 CRISPR to cure sickle cell; FDA rejected; Stem cells use; Celgene spinoff Visit Post
412 Immune Checkpoint Activators (ICA): Dynamic Therapeutic Targets Visit Post
413 Symdeko’s approval; Erytech target solid tumors; Oncologie snapped bavituximab; Merck delivers Visit Post
414 Business Cocktail Visit Post
415 Pandion bags $58M; Carmot Therapeutics grabs $15M; Innovent looks for IPO; Collaboration of Sandoz & Biocon Visit Post
416 Adapsyn signed; Evolus filed; BioNTech signed a deal; Nordisk’s deal Visit Post
417 Notizia Visit Post
418 Business Cocktail Visit Post
419 Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln's anti-malarial drug Visit Post
420 Roche’s Phase 2 data; Celgene and Bluebird’s CAR-T therapy; Regeneron/Sanofi gets results; Allergan on women’s health Visit Post
421 KINECT 4 Study; KindredBio Announces Results; Mylan and Aspen’s Launch; EMA investigates; Amgen’s Repatha Visit Post
422 Targeting cancer through CD40 agonists -A promising future Visit Post
423 Chemists may help solve the air-pollution health crisis Visit Post
424 Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires Visit Post
425 Business Cocktail Visit Post
426 AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes Visit Post
427 Novo petitions FDA;J&J invests; Xarelto’s trial; Roche's Tecentriq Visit Post
428 C-X-C Chemokine Receptor Inhibitors–The Emerging Therapeutic Agents Visit Post
429 Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval Visit Post
430 Isocitrate dehydrogenase (IDH) inhibitors– Emerging Anti-Cancer Therapeutics Visit Post
431 Oral Mucositis – A Common Cancer Therapy Adverse Reaction Visit Post
432 Business cocktail Visit Post
433 Idera’s Phase I Data; DelMar Initiates Trial; Novartis’ study; Humira gets EC approval Visit Post
434 HDAC (Histone Deacetylase) Inhibitors – A Promising Anti-Cancer Target Visit Post
435 CAR-T Phase I trials; ContraVir Announces; Merck acquired; Excision BioTherapeutics bags $10M Visit Post
436 Cancer Globally (Vol. 1, Issue 1) Visit Post
437 Bruton's Tyrosine Kinase (BTK) Inhibitors An Emerging Therapeutic Target Visit Post
438 Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post’s Cannabist; EPX-300 & JOTROL received Designation; New treatment Approved for adults Visit Post
439 PARP Inhibitors making inroads into Ovarian Cancer Visit Post
440 Business CockTail Visit Post
441 CDK 4/6 Inhibitors- The Changing Paradigm for Breast Cancer Treatment Visit Post
442 Allergan sell; AZ, Merck team up; Roche’s MS drug; Chinese API maker receives a warning letter Visit Post
443 Takeda scores; PhRMA launches; Valeant's Obagi; Ex-Novo executive signs Visit Post
444 Gilead faces lawsuit; Herceptin stalled; Lilly revs up, Abemaciclib gets nod; Key Humira patent gets struck down Visit Post
445 Actinic Keratosis – A Warning Sign for Potential Skin Cancer Visit Post
446 Takeda knocks Velcade; FDA nod awaited; Novartis gets approval; Astellas UK dodges; Haegarda set for launch Visit Post
447 Novartis on AMD drug; Hospira recall of vials; Takeda wraps up; FDA bans imports Visit Post
448 J&J nabs; Clovis plots Rubraca; Novartis scores EU approval; Seattle Genetics stops trials Visit Post
449 Sanofi invests; ICER pitches; $6M in NIH; Pfizer, Roche cancer drug pricing Visit Post
450 New cancer drug tested in mice may benefit certain leukaemia patients Visit Post
451 AZ offloads; Pfizer's deal; Takeda’s work on plant; Germany's doc payment Visit Post
452 Gut bacteria can stop cancer drugs from working Visit Post
453 Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins; Alecensa trounces Visit Post
454 Tesaro’s Zejula; Mylan on EpiPen; Ohio sues drugmakers; ATUM, Horizon Discovery Announce deal Visit Post
455 FDA grants accelerated approval to pembrolizumab Visit Post
456 Novartis, slammed by Korean scandal; FDA tweaks; Dendreon eyes; Amgen adds Visit Post
457 Cutaneous Squamous Cell Carcinoma Market & pipeline Visit Post
458 World Ovarian Cancer Day Visit Post
459 Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS; Amgen puts Repatha outcomes for deal Visit Post
460 FDA Approves; AZ nabs; Nordisk settles; Novartis pays Visit Post
461 Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A Visit Post
462 Non-Hodgkin Lymphoma: “Malignant Growth of White Blood Cells” Visit Post
463 Chemotherapy-Induced Nausea and Vomiting Side effects Visit Post
464 Drug shortage; Fujifilm invests; Cobra Biologics to pump $19M; The world's most pricey drugs Visit Post
465 The Snippet: Targeting metabolism in Renal Cell Carcinoma Visit Post
466 Novartis gets CAR-T drug; Shire aims to block; Xeljanz stands; Payer snubs; Lawmakers pass a bill Visit Post
467 Cancer, diabetes and eczema on list; AbbVie's Humira; Teva weighs $2B; Fresenius in buyout talks Visit Post
468 Dengvaxia study; Opdivo racks up; FDA issues plant; Teva's Rimsa fraud; Mission bags Fox grant Visit Post
469 CRISPR finds faults in previous researches Visit Post
470 Valeant's asset-sale; Sanofi coughs up $19.8M; Sanofi's Genzyme; India's Alkem; GSK’s inhalers Visit Post
471 DNA typos to blame for most Cancer Mutations Visit Post
472 Tesaro puts AstraZeneca; XELJANZ® receives; Innovus nabs; Alexion brings Visit Post
473 AKT Inhibitors: A potential Cancer Immunotherapy Target Visit Post
474 Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns Visit Post
475 GSK consolidates DT and TT vaccine, AZ gears up for FDA filing, Novartis comes up with flex pricing, Concordia reports loss Visit Post
476 Colorectal Cancer Awareness Month Visit Post
477 New biomarkers improve standard screening in Pancreatic Cancer Visit Post
478 New biomarkers for screening in Pancreatic Cancer Visit Post
479 Business Cocktail Visit Post
480 NPPA slams; Japan Joins Trump; PCI Pharma Announces Expansion; Merck opens plant; Mylan and Biocon win Visit Post
481 Colorectal Cancer Market Analysis and Market Forecast Visit Post
482 Clinigen and Eisai team up; Sanofi, Lonza enter; Fidia to acquire; J&J completes acquisition Visit Post
483 Colony Stimulating Factor 1 Receptor (CSF1R) and Its connection with Memory Retention Visit Post
484 PMV Raises; Argos Shares Plummet; Cidara Flunks in; Sarepta Sells to Gilead; Novartis and NHS Ayrshire & Arran launch Visit Post
485 Diminishing pipeline of Galectin Inhibitors Visit Post
486 TRAIL Receptor Agonists: Emerging target therapies against Cancer Visit Post
487 OncoTrack develops new biomarkers for colon cancer Visit Post
488 SEC scrutinizes; Acacia meets endpoint; Axovant's dementia drug; Novartis expands; Aurobindo responds Visit Post
489 Familial Adenomatous Polyposis (FAP): A cataclysmic genetic mutation Visit Post
490 FDA approves; Sun Pharma Recalls; Mezzion filed; Sanofi’s antibody to treat Visit Post
491 Statistical Insight on Some Common Cancers Visit Post
492 Subtypes of cervical cancer identified Visit Post
493 Prostate Cancer: Metastases leading to increased incidence in the USA Visit Post
494 FDA accepts; Keytruda takes lead; M Pharmaceutical develops; Merck Deploys Palantir Visit Post
495 Microbiome- A Living Therapy from Guts to Cancer Visit Post
496 Biosimilars: A benchmark in Pharmaceutical Business Visit Post
497 Aurobindo takes top generic spot; Valeant unloads Dendreon; Ipsen strikes $1B deal; Takeda shells out $5.2B Visit Post
498 mTOR Inhibitors-Emerging therapy in various therapeutic areas Visit Post
499 Pfizer uses; FDA approves; EMA approves; Mylan launches Visit Post
500 Ovarian Cancer: The Silent Killers Visit Post
501 Most Common Cancers Visit Post
502 CDC study reveals; Jevtana receives yes; Herantis secures; Immuno-oncology is not cost-effective Visit Post
503 Novartis joins; Sanofi weighs Actelion; Valeant and Takeda's $10B deal; Astellas scouts pipeline Visit Post
504 Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims to beat Visit Post
505 The next generation of 'weaponized antibody' therapies Visit Post
506 EC grants; Pfizer cuts; 27 medicines sold; Keytruda nabs Visit Post
507 High Risk Smoldering Multiple Myeloma Visit Post
508 NgAgo gene-editing, claiming to be a better alternative to CRISPR gene editing, falls into a controversy in peer-reviewed papers Visit Post
509 Novartis Buys; FDA approves; Mayne Pharma Launches; Oxford Genetics Receives Grant Visit Post
510 Phosphoinositide 3-Kinase (PI3k) Inhibitors: Emerging target therapies against Cancer Visit Post
511 CRISPR gene-editing tested in a person for the first time Visit Post
512 Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika Visit Post
513 Estrogen Receptor Positive Breast Cancer: Market Outlook Visit Post
514 Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration; UPS to Acquire Marken Visit Post
515 Biosimilar Market in India Visit Post
516 Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV Visit Post
517 Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi Sankyo Announces; Catalent Pharma Solutions partners with Samsung Bioepis; Celltrion Healthcare and Teva enters into exclusive business collaboration agreement Visit Post
518 Liquid Biopsy: Revolutionary Technique for Cancer Diagnosis Visit Post
519 Merck Focuses its Research on Hard to Treat Cancers Visit Post
520 Cervical Cancer: Current Scenario Visit Post
521 Sygnis AG and ECACC Collaboration; BioNTech and Genentech Partnership; Partnership between Zydus Cadila and Takeda; Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Visit Post
522 PI3Kγ- a molecular switch that controls immune suppression Visit Post
523 HER2 Expression and its Dynamic Functional States Visit Post
524 Novel Genetics Biomarker found by a Group of Researchers May Offer Novel Treatment Approach for Cancer Visit Post
525 Sun Pharma forms partnership; Pfizer and DCRI collaborate; Avara Acquires AZ; ASLAN Pharmaceutical’s Collaboration; Amgen and Servier partnership Visit Post
526 Treatment for esophageal cancer; FDA bans soaps; Dr Reddy's Launches; Cipla Gets Approval Visit Post
527 Recent Pharma Developments related to Immune Checkpoint Activators Visit Post
528 Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys; Insys marketed drug Visit Post
529 Identity Crises Faced by a Venerable Brain-Cancer Cell Line Visit Post
530 PD-1 and PDL-1 Immune Check Point Inhibitors: A Prodigious Revolution in Cancer Treatment Visit Post
531 Bristol Meyers Squibb & AbbVie partner; BioLineRx’s collaboration with MD Anderson Cancer Centre; Partnership between Regeneron Pharmaceuticals and Adicet Bio; Immunotherapy Target Unique Mutations in cancer Visit Post
532 The Curious Case of CRISPR Technology Visit Post
533 Lupin acquired; FDA grants approval; NATCO gets approval; Wockhardt Ltd. gets import alert; Patent fight Visit Post
534 Collaboration provides new insight into cancer treatment Visit Post
535 Pharm Delve Cognizance Visit Post
536 Turning your own skin cells into cancer-killing machines Visit Post
537 A promising immune-stimulating target Visit Post
538 Pancreatic Cancer Market Insights, Epidemiology and Market Forecast-2020 Visit Post
539 Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
540 Acute Myeloid Leukemia- Market Insights, Epidemiology & Forecast Visit Post
541 Antibody-Drug Conjugate Market Insight Visit Post
542 PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 Visit Post
543 LAG-3 Antagonists, TIM-3 Antagonists; OX40 Agonists- Pipeline Insights, 2016 - A DelveInsight Report Visit Post
544 Chimeric Antigen Receptor T cell Immunotherapy Market Analysis and Forecast Visit Post
545 Zemplar Drug Insights, 2016 Visit Post
546 Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Visit Post
547   Pancreatic Cancer-Pipeline Insights, 2016 Visit Post
548 Peripheral Lung Cancer Pipeline Insights, 2016 Visit Post
549 Small interfering RNA (siRNA) Therapeutics Visit Post
550 “Endometrial Cancer - Pipeline Insights, 2015”- A DelveInsight’s Report Visit Post
551 PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 - A DelveInsight Report Visit Post
552 Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015 Visit Post
553 Oral Mucositis Pipeline Insights, 2015- A DelveInsight Report Visit Post
554 Cytotoxic T lymphocyte-associated antigen-4 Market Forecast & Analysis Visit Post
555 DelveInsight’s Oncology based Reports, 2015 Visit Post
556 DelveInsight launches Indication Active Pharmaceutical Ingredient (API) Reports Visit Post
557 Chimeric Antigen Receptor T cell Therapy Market Visit Post
558 Chimeric Antigen Receptor T-cell Therapy Landscape Visit Post
559 Telomerase Inhibitors – An Anti Cancer Approach Visit Post
560 PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2015 Visit Post
561 Antibody-Drug Conjugate and Big Pharmaceutical Companies Visit Post
562 Antibody-Drug Conjugate Market Outlook, 2015 Report in Market Now! Visit Post
563 Next Generation Antibody-Drug Conjugate Therapeutics and Market Analysis Visit Post
564 Antibody-Drug Conjugates Market Outlook, 2015 Report Visit Post
565 Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy Visit Post
566 DelveInsight’s Oncology based Gene Therapy Reports Visit Post
567 Metastatic Prostate Cancer-Pipeline Insights, 2014 Visit Post
568 Oncology Therapeutics Making Big in Coming Years Visit Post